Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Marilynn Larkin, MA
OncoLink
Ultima Vez Modificado: 1 de noviembre del 2001
Although radical prostatectomy (complete surgical removal of the prostate) is the best way to cure cancer that is confined to the prostate, many men choose not to undergo the procedure to avoid the possibility of side effects--in particular, impotence and/or incontinence. But a new study shows that when the procedure is done by a highly experienced surgeon, "side effects are minimal and the outcome is quite good," says lead author Dr. Patrick Walsh, director of the Brady Urological Institute at Johns Hopkins Medical Institutions in Baltimore. Some centers report that only 50% of their patients are continent and 10-30% are potent after radical prostatectomy, but many centers of excellence report "much higher" potency and continence rates, he asserts.
Why the discrepancies? Until now, they were attributed to differences in data collection, Dr. Walsh explained in an interview. It seemed that patients reported worse side effects on anonymous questionnaires than when they spoke directly to their doctors, and this was said to influence side effect rates.
But when Dr. Walsh and colleagues used anonymous questionnaires to assess side effect rates in 64 of their radical prostatectomy patients, they found that 98% had only minor problems, if any, with urinary control one year after the operation. Potency was assessed a year and a half after the procedure, and the results varied with age; 100% of men 30-39 years of age were potent, as were 88% of men aged 40-49, 90% of men aged 50-59, and 75% of men aged 60-67. The results appear in the January issue of the journal Urology.
"Radical prostatectomy is a difficult, demanding operation," Dr. Walsh observes. "Patients who feel that the procedure is the best treatment for their condition should seek out physicians who do a lot of them."
In a separate study in the same journal, the researchers found that videotaping surgery provides an opportunity for surgeons to improve their outcomes. By comparing videotaped surgery of 10 men who remained continent and potent 3 months later with 10 men who were not potent a year after the procedure, Dr. Walsh identified four small variances in surgical technique that were associated with better outcomes; the small changes in technique were needed because of subtle anatomical differences among patients. Videotapes can be used for review by individual surgeons to compare their technique in patients with different outcomes, and also could be swapped among institutions to improve outcomes overall.
Until the advent of PSA testing in the early 1990s, prostate cancer was rarely diagnosed at a curable stage, so the potential benefits of radical prostatectomy did not outweigh the possible side effects. But today, he says, "we're diagnosing most men in the United States with curable disease. Many are young, potent, and have a sexual partner. So the good news is, men diagnosed with early prostate cancer can be saved from dying of metastatic cancer 10 or 15 years later. Now the side effects of this operation should be reduced to the point where you have both extension of life and quality of life."
Ms. Wagner discusses diet during cancer treatment and balancing nutritional needs and side effects. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

